$FBIO News Article - Journey Medical Corporation E
Post# of 122
(Total Views: 152)
Posted On: 07/03/2023 8:05:48 AM
$FBIO News Article - Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul https://marketwirenews.com/news-releases/jour...13535.html
(0)
(0)Fortress Biotech, Inc. (FBIO) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼